Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
SRZN vs KTTA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SRZN Captures Overall Composite Edge (36.0 SELL vs 42.1 HOLD), While KTTA Leads 3–2 on Growth & Valuation Pillars
SRZN Overall Winner
6-Pillar Tally: SRZN 2 – 3 KTTA (1 Tie)
Matrix Metrics: SRZN 4 – 3 KTTA
As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Pasithea Therapeutics Corp. (KTTA) on higher Unified Composite conviction (36.0/100 SELL vs. 42.1/100 HOLD) after splitting the core matrix 4–3 (led by Balance Sheet & Cash Flow, Options & Positioning), while KTTA wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $28.46 (N/M Forward P/E, -485.4% operating margin) versus KTTA at $0.48 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While KTTA currently prints a higher short-term Unified Composite Score (42.1/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. 0.0% operating margin) and revenue trajectory (+408.6% vs. +1498.1% YoY).
- Technical & Structure Timing Caution: SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile KTTA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SRZN vs KTTA
SRZN
Head-to-Head Winner
Surrozen, Inc. Common
$28.46
-7.21% 1D
Market Cap
$642.7M
TTM Revenue
$11M
Forward P/E
N/M
Beta / 30D Vol
1.29β · 73% Vol
Unified Composite Score
36.0
SELL
Tech 15.0
Fund 42.0
Flow 65.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
KTTA
Pasithea Therapeutics Corp. Common Stock
$0.48
-0.48% 1D
Market Cap
$17.7M
TTM Revenue
$486,559
Forward P/E
N/M
Beta / 30D Vol
0.68β · 185% Vol
Unified Composite Score
42.1
HOLD
Tech 20.0
Fund 40.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
6-Pillar Scorecard Institutional Category Breakdown (SRZN 2 – 3 KTTA)
1. Valuation Multiples
KTTA
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
52.1x
36.3x
2. Growth & Scale
KTTA
Revenue Growth (YoY)
+408.6%
+1498.1%
Earnings Growth (YoY)
-37.0%
+0.0%
TTM Revenue (USD)
$11M
$486,559
Market Cap
$642.7M
$17.7M
3. Profitability & Quality
KTTA
Gross Margin
N/A
-0.5%
Operating Margin
-485.4%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-62.8%
-88.8%
4. Balance Sheet & Cash Flow
SRZN
Cash Generation (TTM)
-$31M
-$18M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$95M Net Cash
$1.31 Book/Sh · -88.8% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
SRZN
Options Structure Phase
CONSOLIDATION
UNCLASSIFIED
Current IV / %ile
72.0% (13th %ile)
N/A (N/A)
Put/Call OI Skew
21.00x (Put-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Distribution
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SRZN (4) vs KTTA (3)| Institutional Metric | SRZN | KTTA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $642.7M | $17.7M | SRZN | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +408.6% | +1498.1% | KTTA | |
| Operating Margin (TTM) | -485.4% | 0.0% | KTTA | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -62.8% | -88.8% | SRZN | |
| 52-Week Range Position | 63% ($13–$38) | 11% ($0–$2) | SRZN | |
| Beta / 30D Volatility | 1.29β · 73% Vol | 0.68β · 185% Vol | SRZN | |
| Unified Institutional Score | 36.0 / 100 (SELL) | 42.1 / 100 (HOLD) | KTTA | |
| Trailing 12M Revenue (USD) | $11M | $486,559 | Scale | |
| Gross Profit Margin (TTM) | N/A | -0.5% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 52.1x EV/Rev | N/M PEG · 36.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$31M ($95M Net Cash) | -$18M ($1.31 Book/Sh · -88.8% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SRZN +3.0 pp
3M Horizon
SRZN +23.94 pp
6M Horizon
SRZN +39.52 pp
1Y Horizon
SRZN +110.22 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SRZN Revenue | KTTA Revenue | SRZN Op. Margin | KTTA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2021 | N/A | $0M | N/A | -29925.7% | KTTA |
| FY2022 | $10M | $0M | -354.7% | -2587.3% | SRZN |
| FY2024 | $10M | N/A | -239.7% | N/A | SRZN |
| FY2025 | $0M | N/A | -1210.6% | N/A | SRZN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SRZN
CONSOLIDATION
Current IV
72.0%
IV Percentile
13th %ile
Put/Call OI Skew
21.00x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
KTTA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact KTTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SRZN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
KTTA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ SRZN vs KTTA Key Questions & Quantitative Answers
As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Pasithea Therapeutics Corp. (KTTA) on higher Unified Composite conviction (36.0/100 SELL vs. 42.1/100 HOLD) after splitting the core matrix 4–3 (led by Balance Sheet & Cash Flow, Options & Positioning), while KTTA wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $28.46 (N/M Forward P/E, -485.4% operating margin) versus KTTA at $0.48 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While KTTA currently prints a higher short-term Unified Composite Score (42.1/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. 0.0% operating margin) and revenue trajectory (+408.6% vs. +1498.1% YoY). Technical & Structure Timing Caution: SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile KTTA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KTTA leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with KTTA at +1498.1% YoY revenue growth and +0.0% YoY earnings growth on $486,559 TTM revenue (-0.5% gross margin, 0.0% operating margin). Across the 4-period historical trajectory (FY2021 to FY2025), SRZN cumulative revenue shifted +0.0% while KTTA shifted N/A. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KTTA.
KTTA screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 52.1x EV/Revenue (unreported FCF margin), whereas KTTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 36.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus KTTA (-88.8% ROE) capital efficiency.
In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (13th %ile, Compressed (<25th %ile)), a 21.00x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 73% Vol realized risk). By comparison, KTTA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 185% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
KTTA vs SRZN · Reverse Pair
SRZN vs FTH
· Sector Peer
SRZN vs JSPR
· Sector Peer
SRZN vs TIL
· Sector Peer
KTTA vs QNRX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma